Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

比马前列素 睫毛 医学 少毛症 随机对照试验 皮肤病科 不利影响 外科 眼科 内科学 青光眼 拉坦前列素 化学 基因 生物 生物化学 遗传学
作者
Dee Anna Glaser,Parwez Hossain,William Perkins,Tamara Griffiths,Gurpreet S. Ahluwalia,Emily Weng,Frederick C. Beddingfield
出处
期刊:British Journal of Dermatology [Wiley]
卷期号:172 (5): 1384-1394 被引量:36
标识
DOI:10.1111/bjd.13443
摘要

Bimatoprost ophthalmic solution 0·03% is approved in several countries for the treatment of eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis.To evaluate the long-term safety and efficacy of bimatoprost in patients with idiopathic or chemotherapy-induced hypotrichosis.This multicentre, double-masked, randomized, parallel-group study included two 6-month treatment periods [treatment period 1 (TP1) and treatment period 2 (TP2)]. Patients with idiopathic hypotrichosis were randomized to three treatment groups: (i) bimatoprost (TP1 and TP2); (ii) bimatoprost (TP1) and vehicle (TP2); and (iii) vehicle (TP1) and bimatoprost (TP2). Patients with chemotherapy-induced hypotrichosis were randomized to two treatment groups: (i) bimatoprost or vehicle (TP1) and (ii) bimatoprost (TP2). Primary end point was a composite of at least a one-grade improvement in investigator-assessed Global Eyelash Assessment and at least a three-point improvement in patient-reported Eyelash Satisfaction Questionnaire Domain 2 at month 4. Secondary measures included digitally assessed eyelash characteristics.The primary efficacy end point was met in both populations (idiopathic responder rate was 40·2% for bimatoprost vs. 6·8% for vehicle; postchemotherapy responder rate was 37·5% for bimatoprost vs. 18·2% for vehicle). Efficacy by month 6 was maintained (idiopathic) or enhanced (postchemotherapy) at 12 months. Treatment effects were maintained for approximately 2 months but markedly diminished 4-6 months following treatment cessation in patients with idiopathic hypotrichosis. No drug-related serious adverse events were reported.Daily treatment with bimatoprost ophthalmic solution 0·03% for 1 year was effective and well tolerated in patients with idiopathic and chemotherapy-induced hypotrichosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
烟花应助haha采纳,获得10
2秒前
Jasper应助genoy采纳,获得10
2秒前
Jason发布了新的文献求助10
2秒前
cc发布了新的文献求助30
2秒前
小蘑菇应助chenjingjing采纳,获得10
4秒前
shinysparrow应助内向友桃采纳,获得10
4秒前
笑、发布了新的文献求助10
5秒前
上官若男应助神奇的种子采纳,获得10
6秒前
6秒前
cc完成签到,获得积分10
8秒前
11秒前
海凌子完成签到,获得积分10
13秒前
13秒前
haha完成签到,获得积分10
14秒前
亦木完成签到,获得积分10
15秒前
笑、完成签到,获得积分10
17秒前
CipherSage应助Ly采纳,获得10
19秒前
19秒前
未央完成签到,获得积分10
21秒前
yyauthor完成签到,获得积分10
22秒前
cqs完成签到,获得积分10
22秒前
头上烧完成签到,获得积分10
23秒前
hxyhxy完成签到 ,获得积分10
23秒前
彭于晏应助Qianyu采纳,获得10
24秒前
酷波er应助Jason采纳,获得10
27秒前
咦沙发布了新的文献求助10
27秒前
28秒前
宋泽艺完成签到 ,获得积分10
30秒前
刘艺娜完成签到,获得积分10
33秒前
森宝完成签到,获得积分10
34秒前
34秒前
土又鸟完成签到 ,获得积分10
34秒前
Liv发布了新的文献求助10
38秒前
王小白完成签到,获得积分10
38秒前
张泽崇完成签到,获得积分0
39秒前
42秒前
42秒前
打打应助王小白采纳,获得10
43秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
薩提亞模式團體方案對青年情侶輔導效果之研究 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2392328
求助须知:如何正确求助?哪些是违规求助? 2096863
关于积分的说明 5283151
捐赠科研通 1824481
什么是DOI,文献DOI怎么找? 909913
版权声明 559923
科研通“疑难数据库(出版商)”最低求助积分说明 486236